Stock events for Lisata Therapeutics, Inc. (LSTA)
Over the past six months, Lisata Therapeutics' stock has trended upward. Key events include the acquisition by Kuva Labs, Inc., the termination of the Qilu Pharmaceutical agreement, positive preclinical data regarding certepetide, the report of Q3 2025 financial results, and positive CENDIFOX trial results.
Demand Seasonality affecting Lisata Therapeutics, Inc.’s stock price
Based on historical stock price data, there appears to be some seasonality in investor demand for Lisata Therapeutics Inc. (LSTA) stock. March and November offer the highest probability of positive returns, while October has historically shown the lowest probability of positive returns.
Overview of Lisata Therapeutics, Inc.’s business
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other serious diseases. Formed in September 2022 through a merger, its lead product candidate, certepetide, aims to enhance drug delivery to tumors. Certepetide has received Orphan Drug and Fast Track status from the FDA. The company is progressing certepetide through multiple clinical studies and has business development activities, including agreements with Catalent, Inc. and GATC Health.
LSTA’s Geographic footprint
Lisata Therapeutics is headquartered in Basking Ridge, New Jersey, United States. Its stock is traded on the NASDAQ exchange under the ticker LSTA and is listed on several European stock exchanges. A previous agreement with Qilu Pharmaceutical for certepetide in the Greater China region was terminated in January 2026, with all rights reverting to Lisata.
LSTA Corporate Image Assessment
Lisata Therapeutics has received positive recognition for its scientific advancements, including the 2025 BioTech Breakthrough Award. Positive preclinical results and data from its CENDIFOX trial have also contributed positively to its reputation. However, some historical online comments suggest negative sentiment among certain retail investor segments in the past. Recent analyst ratings show a consensus of "Strong Buy" from two analysts, with a predicted upside, while other analysts have a "Hold" consensus.
Ownership
Lisata Therapeutics has a mixed ownership structure, including institutional investors, insiders, and retail investors. Institutional investors hold approximately 8.11% to 8.94% of the stock. Insiders hold a significant portion, around 10.78% to 994.21%. Retail investors hold a substantial portion of the stock, with some sources indicating around 81.81%.
